Prostate cancer: Focal One®, a revolutionary treatment
 
Geneva:
+4122 840 33 34
 
Moscow:
+7(903)720 80 57

Prostate cancer: Focal One®, a revolutionary treatment

Focal One® is a computer-controlled medical device for the treatment of localised prostate cancer by focused ultrasound (HIFU = High Intensity Focused Ultrasound). The energy is delivered via an endorectal probe. The ultrasound waves travel through the rectal wall and are focused on a part of the prostate. This focusing produces intense heat, resulting in tissue destruction within the target area. The treatment lasts between 30 minutes and 2 hours and can be performed under loco-regional anaesthesia.

Focal One® is a non-invasive treatment option that allows for a precise, local treatment in one session, that can be repeated if necessary, with a short hospital stay and few side effects. In the event of incomplete results, the choice of therapeutic options is wide and includes retreatment with Focal One®.

Focal One® may be indicated as:

  • a first line option for patients with localised cancer, stage T1-T2 (Gleason 6 or 7, PSA less than 15), according to their age and general condition.
  • a salvage therapy option for patients with local recurrence of prostate cancer initially treated by radiotherapy.

HIFU for prostate cancer

HIFU uses a high intensity convergent ultrasound beam generated by piezoelectric transducers. This focusing of ultrasound waves into one point greatly increases the temperature around the focal point, thus resulting in tumour destruction i.e. pathological biological tissue.

The application of HIFU for prostate cancer treatment involves focusing high intensity focused ultrasound to destroy, by heat, prostatic tissue affected by cancer, without damaging surrounding tissue. This technique is non-invasive because it avoids incision, allows loco-regional anaesthesia and limits the characteristic complications of prostate cancer treatment (incontinence or impotence).

Clinical results

In 2013 and 2014, two prospective cohort studies demonstrated the long-term (10 years) results of whole gland HIFU as a first-line option and have validated its effectiveness: according to the cancer risk, the specific survival rate at 10 years is between 92 and 99%; survival rate without metastases at 10 years is between 86% and 100%. These results, which are completely comparable to the best radical surgery results, demonstrate that HIFU is an effective first-line treatment option for localised prostate cancer.

Comments
Articles
Patient registration form
Topics
Examination Incorpore
nutrition
oncology
prevention
cancer
dermatology
age management
Anti-aging
detoxification
skin
heavy metal
diagnosis
cardiology
immunology
stem cells
weight management
oncology treatment
liver detox
DNA
Genetics
allergy
pain
Fertility
Examination partner centres
gastroenterology
covid19
weight loss
cosmetology
liver
infertility
chelation
Sleep
gynecology
urology
radiology
neurology
check-up
skincare
pregnancy
Hepatitis C
rehabilitation
headache
breast cancer
candida
arsenic
anti-aging
obstetrics
joints
immune system
Дерматология
heart MRI
immunotherapy
NAD+
Blood pressure
mesotherapy
probiotics
Apnea
tinnitus
ulcer
abdominal pain
pancreas
research
sexuality
beau-rivage
nutrigenomics
migraine
menopause
telomere
gastritis
flu vaccine
regeneration
PRP
andropause
light therapy
excimer laser
psoriasis
hyaluronic acid
sugar
obstertics
rhesus factor
Allergology
preventiion
gastroscopy
brain surgery awake
mastectomy
digestion
mammography
cellmen
cellcosmet
herniated disc
flu
magnesium
R-loops
Omega-3
shoulder
hand
intestinal flora
depression
iron
second opinion
food intolerances
reflexology
food
vitamin b12
mercury
water
erectile dysfunction
back pain
hip
knee
beauty
exercise
sports
cholesterol
stress
vitamin K
narcosis
diabetes
cellulite
acnea
migraines
chronic headaches
diet
oncoloy
reconstruction
blood test
endometriosis
acne
LED therapy
biopsy
liquid biopsy
oral checkup
propofole
dermatitis
hormones
general surgery
nephrology
kidney
ophthalmology
plastic surgery
lungs
pneumology
proctology
pomegranate
rheumatology
orthopedics
colonoscopy
endocrinology
Treatment programs